Immunotherapy and biologics in the management of IgE-mediated food allergy: Systematic review and meta-analyses of efficacy and safety.
biologics
egg
food allergy
immunotherapy
milk
omalizumab
peanut
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
15 May 2024
15 May 2024
Historique:
revised:
01
03
2024
received:
30
05
2023
accepted:
22
03
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
15
5
2024
Statut:
aheadofprint
Résumé
Food allergy (FA) is a potentially life-threatening chronic condition that is becoming an increasing public health problem worldwide. This systematic review (SR) was carried out to inform the development of clinical recommendations on the treatment of IgE-mediated FA with biologics and/or IT for the update of the EAACI guidelines. A SR of randomized-controlled trials or quasi-controlled trials was carried out. Studies were identified via comprehensive search strategies in Medline, Embase, and Cochrane Library, up to April 2022. Human adults, children, and adolescents with IgE-mediated FA. IT and/or biologics. Placebo or standard-of-care (allergen avoidance). Efficacy (desensitization, sustained unresponsiveness (SU), remission), quality of life, and safety (systemic and local adverse reactions (AR)). The Cochrane RoB tool was used to assess the risk of bias. It was reported according to PRISMA and registered in PROSPERO CRD4202229828. After screening, 121 studies were included (111 for IT and 10 for biologics). Most studies had a high risk of bias and showed high heterogeneity in design and results. Metanalysis showed a positive effect of biologics and IT in terms of relative risk (RR) for achieving tolerance to the culprit food compared to avoidance or placebo. Omalizumab for any FA showed a RR of 2.17 [95% confidence interval: 1.22, 3.85]. For peanut allergy, oral IT (OIT) had a RR of 11.94 [1.76, 80.84] versus avoidance or placebo, sublingual IT (SLIT) had a RR of 3.00 [1.04, 8.66], and epicutaneous IT (EPIT) of 2.16 [1.56, 3.00]. OIT had a RR of 5.88 [2.27, 15.18] for cow's milk allergy, and of 3.43 [2.24, 5.27] for egg allergy. There was insufficient data on SLIT or EPIT for the treatment of egg and milk allergies. Most ARs reported were mild. For OIT the most common AR involved the gastrointestinal system and for EPIT, AR's most commonly affected the skin. There was limited data on severe or life-threatening ARs. There was limited evidence for long term efficacy and quality of life. In conclusion, biologics and IT, alone or in combination, are effective in achieving desensitization while on active treatment but more evidence is needed on long-term tolerance as current evidence is not of high quality. Adverse events while on therapy are generally mild to moderate but a long-term comprehensive safety profile is missing. There is a critical need to optimize and standardize desensitization protocols and outcome measures to facilitate our understanding of the efficacy and safety as well as to allow for comparison between interventions.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Academy of Allergy and Clinical Immunology
Informations de copyright
© 2024 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Lyons SA, Clausen M, Knulst AC, et al. Prevalence of food sensitization and food allergy in children across Europe. J Allergy Clin Immunol Pract. 2020;8(8):2736‐2746. e9.
Elghoudi A, Narchi H. Food allergy in children‐the current status and the way forward. World J Clin Pediatr. 2022;11(3):253‐269.
Proctor KB, Tison K, Estrem HH, et al. A systematic review of parent report measures assessing the psychosocial impact of food allergy on patients and families. Allergy. 2022;77(5):1347‐1359.
Bilaver LA, Chadha AS, Doshi P, O'Dwyer L, Gupta RS. Economic burden of food allergy: a systematic review. Ann Allergy Asthma Immunol. 2019;122(4):373‐380.e1.
Protudjer JL, Jansson SA, Heibert Arnlind M, et al. Household costs associated with objectively diagnosed allergy to staple foods in children and adolescents. J Allergy Clin Immunol Pract. 2015;3(1):68‐75.
Warren CM, Turner PJ, Chinthrajah RS, Gupta RS. Advancing food allergy through epidemiology: understanding and addressing disparities in food allergy management and outcomes. J Allergy Clin Immunol Pract. 2021;9(1):110‐118.
Meyer R. Nutritional disorders resulting from food allergy in children. Pediatr Allergy Immunol. 2018;29(7):689‐704.
FDA. FDA approves first drug for treatment of peanut allergy for children. 2020.
Rodriguez Del Rio P, Alvarez‐Perea A, Blumchen K, et al. Food immunotherapy practice: nation differences across Europe, the FIND project. Allergy. 2021;77:920‐932.
Fiocchi A, Pecora V, Valluzzi RL, Fierro V, Mennini M. Use of biologics in severe food allergies. Curr Opin Allergy Clin Immunol. 2017;17(3):232‐238.
Muraro A, Werfel T, Hoffmann‐Sommergruber K, et al. EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. Allergy. 2014;69(8):1008‐1025.
Pajno GB, Fernandez‐Rivas M, Arasi S, et al. EAACI guidelines on allergen immunotherapy: IgE‐mediated food allergy. Allergy. 2018;73(4):799‐815.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40‐46.
Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Sterne J et al. A Cochrane Risk Of Bias Assessment Tool: for Non‐Randomized Studies of Interventions (ACROBATNRSI), Version 1.0.0, 24 September 2014. 2014.
The Cochrane Collaboration. Review Manager (RevMan). 2020.
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924‐926.
Schünemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336(7653):1106‐1110.
Brozek JL, Akl EA, Alonso‐Coello P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy. 2009;64(5):669‐677.
Brożek JL, Akl EA, Compalati E, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy. 2011;66(5):588‐595.
Brozek JL, Akl EA, Jaeschke R, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy. 2009;64(8):1109‐1116.
Andorf S, Purington N, Kumar D, et al. A phase 2 randomized controlled multisite study using Omalizumab‐facilitated rapid desensitization to test continued vs discontinued dosing in Multifood allergic individuals. EClinicalMedicine. 2019;7:27‐38.
Andorf S, Purington N, Block WM, et al. Anti‐IgE treatment with oral immunotherapy in multifood allergic participants: a double‐blind, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2018;3(2):85‐94.
Chinthrajah S, Cao S, Liu C, et al. Phase 2a randomized, placebo‐controlled study of anti–IL‐33 in peanut allergy. JCI Insight. 2019;4(22):e131347.
Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti‐IgE therapy in patients with peanut allergy. N Engl J Med. 2003;348(11):986‐993.
MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017;139(3):873‐881.e8.
NCT00932282. Peanut Oral Immunotherapy and Anti‐Immunoglobulin E (IgE) for Peanut Allergy. https://clinicaltrials.gov/show/NCT00932282 2009.
Sampson HA, Leung DYM, Burks AW, et al. A phase II, randomized, double‐blind, parallel‐group, placebo‐controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127(5):1309‐10.e1.
Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high‐risk peanut‐allergic patients. J Allergy Clin Immunol. 2013;132(6):1368‐1374.
Takahashi M, Soejima K, Taniuchi S, et al. Oral immunotherapy combined with omalizumab for high‐risk cow's milk allergy: a randomized controlled trial. Sci Rep. 2017;7(1):17453.
Wood RA, Kim JS, Lindblad R, et al. A randomized, double‐blind, placebo‐controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy. J Allergy Clin Immunol. 2016;137(4):1103‐1110.e11.
Akashi M, Yasudo H, Narita M, et al. Randomized controlled trial of oral immunotherapy for egg allergy in Japanese patients. Pediatr Int. 2017;59(5):534‐539.
Amat F, Kouche C, Gaspard W, et al. Is a slow‐progression baked milk protocol of oral immunotherapy always a safe option for children with cow's milk allergy? A randomized controlled trial. Clin Exp Allergy. 2017;47(11):1491‐1496.
Anagnostou K, Islam S, King Y, et al. Study of induction of tolerance to Oral Peanut: a randomised controlled trial of desensitisation using peanut oral immunotherapy in children (STOP II). Efficacy Mech Eval. 2014;1:1‐56.
Anagnostou K, Islam S, King Y, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet (London, England). 2014;383(9925):1297‐1304.
Babaie D, Ebisawa M, Soheili H, et al. Oral wheat immunotherapy: long‐term follow‐up in children with wheat anaphylaxis. Int Arch Allergy Immunol. 2021;183:1‐9.
Bellach J, Schwarz V, Ahrens B, et al. Randomized placebo‐controlled trial of hen's egg consumption for primary prevention in infants. J Allergy Clin Immunol. 2017;139(5):1591‐1599.e2.
Bird JA, Feldman M, Arneson A, et al. Modified peanut oral immunotherapy protocol safely and effectively induces desensitization. J Allergy Clin Immunol Pract. 2015;3(3):433‐435.e3.
Bird JA, Spergel JM, Jones SM, et al. Efficacy and safety of AR101 in Oral immunotherapy for Peanut allergy: results of ARC001, a randomized, double‐blind, placebo‐controlled phase 2 clinical trial. J Allergy Clin Immunol Pract. 2018;6(2):476‐485.e3.
Blumchen K, Trendelenburg V, Ahrens F, et al. Efficacy, safety, and quality of life in a multicenter, randomized, placebo‐controlled trial of low‐dose peanut oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol Pract. 2019;7(2):479‐491.e10.
Blumchen K, Ulbricht H, Staden U, et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol. 2010;126(1):83‐91.e1.
Buchanan AD, Green TD, Jones SM, et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol. 2007;119(1):199‐205.
Burks AW, Jones SM, Wood RA, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med. 2012;367(3):233‐243.
Burks AW, Wood RA, Jones SM, et al. Sublingual immunotherapy for peanut allergy: long‐term follow‐up of a randomized multicenter trial. J Allergy Clin Immunol. 2015;135(5):1240‐1248.e1‐3.
Caminiti L, Passalacqua G, Barberi S, et al. A new protocol for specific oral tolerance induction in children with IgE‐mediated cow's milk allergy. Allergy Asthma Proc. 2009;30(4):443‐448.
Caminiti L, Pajno GB, Crisafulli G, et al. Oral immunotherapy for egg allergy: a double‐blind placebo‐controlled study, with Postdesensitization follow‐up. J Allergy Clin Immunol Pract. 2015;3(4):532‐539.
Carraro S, Frigo AC, Perin M, et al. Impact and oral immunotherapy on quality of life in children with cow milk allergy: a pilot study. Int J Immunopathol Pharmacol. 2012;25(3):793‐798.
Chinthrajah RS, Purington N, Andorf S, et al. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double‐blind, placebo‐controlled, phase 2 study. Lancet (London, England). 2019;394(10207):1437‐1449.
Dantzer J, Dunlop J, Psoter KJ, Keet C, Wood R. Efficacy and safety of baked milk oral immunotherapy in children with severe milk allergy: a randomized, double‐blind, placebo‐controlled phase 2 trial. J Allergy Clin Immunol. 2021;149:1383‐1391.e17.
Davis CM, Anagnostou A, Devaraj S, et al. Maximum dose food challenges reveal transient sustained unresponsiveness in peanut oral immunotherapy (POIMD study). J Allergy Clin Immunol Pract. 2022;10(2):566‐576.e6.
de Boissieu D, Dupont C. Sublingual immunotherapy for cow's milk protein allergy: a preliminary report. Allergy. 2006;61(10):1238‐1239.
Dello Iacono I, Tripodi S, Calvani M, Panetta V, Verga MC, Miceli Sopo S. Specific oral tolerance induction with raw hen's egg in children with very severe egg allergy: a randomized controlled trial. Pediatr Allergy Immunol. 2013;24(1):66‐74.
Dupont C, Kalach N, Soulaines P, Legoué‐Morillon S, Piloquet H, Benhamou PH. Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol. 2010;125(5):1165‐1167.
Ebrahimi M, Gharagozlou M, Mohebbi A, Hafezi N, Azizi G, Movahedi M. The efficacy of oral immunotherapy in patients with cow's milk allergy. Iran J Allergy Asthma Immunol. 2017;16(3):183‐192.
Elizur A, Appel MY, Nachshon L, et al. Cashew oral immunotherapy for desensitizing cashew‐pistachio allergy (NUT CRACKER study). Allergy. 2022;77:1863‐1872.
Enrique E, Malek T, Pineda F, et al. Sublingual immunotherapy for hazelnut food allergy: a follow‐up study. Ann Allergy Asthma Immunol. 2008;100(3):283‐284.
Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double‐blind, placebo‐controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;116(5):1073‐1079.
Escudero C, Rodríguez Del Río P, Sánchez‐García S, et al. Early sustained unresponsiveness after short‐course egg oral immunotherapy: a randomized controlled study in egg‐allergic children. Clin Exp Allergy. 2015;45(12):1833‐1843.
Factor JM, Mendelson L, Lee J, Nouman G, Lester MR. Effect of oral immunotherapy to peanut on food‐specific quality of life. Ann Allergy Asthma Immunol. 2012;109(5):348‐352. e2.
Fauquert JL, Michaud E, Pereira B, et al. Peanut gastrointestinal delivery oral immunotherapy in adolescents: results of the build‐up phase of a randomized, double‐blind, placebo‐controlled trial (PITA study). Clin Exp Allergy. 2018;48(7):862‐874.
Fernandez‐Rivas M, Vereda A, Vickery BP, et al. Open‐label follow‐on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy. Allergy. 2021;77:991‐1003.
Fernández‐Rivas M, Garrido Fernández S, Nadal JA, et al. Tabar, randomized double‐blind, placebo‐controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy. 2009;64(6):876‐883.
Fleischer DM, Shreffler WG, Campbell DE, et al. Long‐term, open‐label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3‐year results. J Allergy Clin Immunol. 2020;146(4):863‐874.
Fleischer DM, Burks AW, Vickery BP, et al. Sublingual immunotherapy for peanut allergy: a randomized, double‐blind, placebo‐controlled multicenter trial. J Allergy Clin Immunol. 2013;131(1):119‐127.e1‐7.
Fleischer DM, Greenhawt M, Sussman G, et al. Effect of Epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES randomized clinical trial. JAMA. 2019;321(10):946‐955.
Fuentes‐Aparicio V, Alvarez‐Perea A, Infante S, Zapatero L, D'Oleo A, Alonso‐Lebrero E. Specific oral tolerance induction in paediatric patients with persistent egg allergy. Allergol Immunopathol. 2013;41(3):143‐150.
García‐Ara C, Pedrosa M, Belver MT, Martín‐Muñoz MF, Quirce S, Boyano‐Martínez T. Efficacy and safety of oral desensitization in children with cow's milk allergy according to their serum specific IgE level. Ann Allergy Asthma Immunol. 2013;110(4):290‐294.
Ghobadi Dana V, Fallahpour M, Shoormasti RS, et al. Oral immunotherapy in patients with IgE mediated reactions to egg white: a clinical trial study. Immunol Investig. 2022;51(3):630‐643.
Giavi S, Vissers YM, Muraro A, et al. Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. Allergy. 2016;71(11):1575‐1584.
Gomez F, Bogas G, Gonzalez M, et al. The clinical and immunological effects of Pru p 3 sublingual immunotherapy on peach and peanut allergy in patients with systemic reactions. Clin Exp Allergy. 2017;47(3):339‐350.
Hofmann AM, Scurlock AM, Jones SM, et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol. 2009;124(2):286‐291.e1‐6.
Howe LC, Leibowitz KA, Perry MA, et al. Changing patient mindsets about non‐life‐threatening symptoms during oral immunotherapy: a randomized clinical trial. J Allergy Clin Immunol Pract. 2019;7(5):1550‐1559.
Inuo C, Tanaka K, Suzuki S, et al. Oral immunotherapy using partially hydrolyzed formula for cow's milk protein allergy: a randomized, controlled trial. Int Arch Allergy Immunol. 2018;177(3):259‐268.
Itoh‐Nagato N, Inoue Y, Nagao M, et al. Desensitization to a whole egg by rush oral immunotherapy improves the quality of life of guardians: a multicenter, randomized, parallel‐group, delayed‐start design study. Allergol Int. 2018;67(2):209‐216.
Jones SM, Pons L, Roberts JL, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 2009;124(2):292‐300.
Jones SM, Burks AW, Keet C, et al. Long‐term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. J Allergy Clin Immunol. 2016;137(4):1117‐1127.e10.
Jones SM, Kim EH, Nadeau KC, et al. Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the immune tolerance network IMPACT trial): a randomised placebo‐controlled study. Lancet (London, England). 2022;399(10322):359‐371.
Jones SM, Sicherer SH, Burks AW, et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol. 2017;139(4):1242‐1252.e9.
Kim EH, Yang L, Ye P, et al. Long‐term sublingual immunotherapy for peanut allergy in children: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2019;144(5):1320‐1326.e1.
Kim EH, Bird JA, Kulis M, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2011;127(3):640‐646.e1.
Kim EH, Perry TT, Wood RA, et al. Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy. J Allergy Clin Immunol. 2020;146(4):851‐862.e10.
Kopac P, Rudin M, Gentinetta T, et al. Continuous apple consumption induces oral tolerance in birch‐pollen‐associated apple allergy. Allergy. 2012;67(2):280‐285.
Kukkonen AK, Uotila R, Malmberg LP, Pelkonen AS, Mäkelä MJ. Double‐blind placebo‐controlled challenge showed that peanut oral immunotherapy was effective for severe allergy without negative effects on airway inflammation. Acta Paediatr. 2017;106(2):274‐281.
Lauener R, Eigenmann PA, Wassenberg J, et al. Oral immunotherapy with partially hydrolyzed wheat‐based cereals: a pilot study. Clin Med Insights Pediatr. 2017;11:1179556517730018.
Lee JH, Kim WS, Kim H, Hahn YS. Increased cow's milk protein‐specific IgG4 levels after oral desensitization in 7‐ to 12‐month‐old infants. Ann Allergy Asthma Immunol. 2013;111(6):523‐528.
Longo G, Barbi E, Berti I, et al. Specific oral tolerance induction in children with very severe cow's milk‐induced reactions. J Allergy Clin Immunol. 2008;121(2):343‐347.
Maeda M, Imai T, Ishikawa R, et al. Effect of oral immunotherapy in children with milk allergy: the ORIMA study. Allergol Int. 2021;70(2):223‐228.
Mansouri M, Movahhedi M, Pourpak Z, et al. Oral desensitization in children with IgE‐mediated cow's milk allergy: a prospective clinical trial. Tehran‐Univ‐Med‐J. 2007;65(5):11‐18.
Martín‐Muñoz MF, Alonso Lebrero E, Zapatero L, et al. Egg OIT in clinical practice (SEICAP II): maintenance patterns and desensitization state after normalizing the diet. Pediatr Allergy Immunol. 2019;30(2):214‐224.
Martín‐Muñoz MF, Belver MT, Alonso Lebrero E, et al. Egg oral immunotherapy in children (SEICAP I): daily or weekly desensitization pattern. Pediatr Allergy Immunol. 2019;30(1):81‐92.
Martorell A, De la Hoz B, Ibáñez MD, et al. Oral desensitization as a useful treatment in 2‐year‐old children with cow's milk allergy. Clin Exp Allergy. 2011;41(9):1297‐1304.
Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE‐mediated cow's milk allergy. Allergy. 2004;59(9):980‐987.
Meglio P, Giampietro PG, Carello R, Gabriele I, Avitabile S, Galli E. Oral food desensitization in children with IgE‐mediated hen's egg allergy: a new protocol with raw hen's egg. Pediatr Allergy Immunol. 2013;24(1):75‐83.
Miura Y, Nagakura KI, Nishino M, et al. Long‐term follow‐up of fixed low‐dose oral immunotherapy for children with severe cow's milk allergy. Pediatr Allergy Immunol. 2021;32(4):734‐741.
Moneret‐Vautrin DA, Petit N, Parisot L, et al. Efficiency and safety of oral immunotherapy protocols in peanut allergy. Pilot study on 51 patients. Revue Francaise d'Allergologie. 2010;50(5):434‐442.
Mori F, Cianferoni A, Brambilla A, et al. Side effects and their impact on the success of milk oral immunotherapy (OIT) in children. Int J Immunopathol Pharmacol. 2017;30(2):182‐187.
Morisset M, Moneret‐Vautrin DA, Guenard L, et al. Oral desensitization in children with milk and egg allergies obtains recovery in a significant proportion of cases. A randomized study in 60 children with cow's milk allergy and 90 children with egg allergy. Eur Ann Allergy Clin Immunol. 2007;39(1):12‐19.
Nachshon L, Goldberg MR, Levy MB, et al. Efficacy and safety of sesame Oral immunotherapy‐a real‐world, single‐center study. J Allergy Clin Immunol Pract. 2019;7(8):2775‐2781.e2.
Nagakura KI, Yanagida N, Sato S, et al. Low‐dose‐oral immunotherapy for children with wheat‐induced anaphylaxis. Pediatr Allergy Immunol. 2020;31(4):371‐379.
Nagakura KI, Sato S, Miura Y, et al. A randomized trial of oral immunotherapy for pediatric cow's milk‐induced anaphylaxis: heated vs unheated milk. Pediatr Allergy Immunol. 2021;32(1):161‐169.
Narisety SD, Skripak JM, Steele P, et al. Open‐label maintenance after milk oral immunotherapy for IgE‐mediated cow's milk allergy. J Allergy Clin Immunol. 2009;124(3):610‐612.
NCT00597675. Oral Immunotherapy for Peanut Allergy (PMIT). https://clinicaltrials.gov/show/NCT00597675 2008.
NCT01324401. Oral Peanut Immunotherapy. https://clinicaltrials.gov/show/NCT01324401 2011.
NCT01373242. Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance. https://clinicaltrials.gov/show/NCT01373242 2011.
NCT01846208. Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy. https://clinicaltrials.gov/show/NCT01846208 2013.
NCT02304991. FARE Peanut SLIT and Early Tolerance Induction. https://clinicaltrials.gov/show/NCT02304991 2014.
NCT04056299. Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy. https://clinicaltrials.gov/show/NCT04056299 2019.
Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol. 1997;99(6 Pt 1):744‐751.
Netting M, Gold M, Quinn P, el‐Merhibi A, Penttila I, Makrides M. Randomised controlled trial of a baked egg intervention in young children allergic to raw egg but not baked egg. World Allergy Organ J. 2017;10(1):22.
Niggemann B, von Berg A, Bollrath C, et al. Safety and efficacy of a new extensively hydrolyzed formula for infants with cow's milk protein allergy. Pediatr Allergy Immunol. 2008;19(4):348‐354.
Nowak‐Węgrzyn A, Wood RA, Nadeau KC, et al. Multicenter, randomized, double‐blind, placebo‐controlled clinical trial of vital wheat gluten oral immunotherapy. J Allergy Clin Immunol. 2019;143(2):651‐661.e9.
O'B Hourihane J, Beyer K, Abbas A, et al. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double‐blind, randomised, placebo‐controlled phase 3 trial. Lancet Child Adolesc Health. 2020;4(10):728‐739.
Ogura K, Yanagida N, Sato S, et al. Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: a multicenter randomized study. World Allergy Organ J. 2020;13(10):100463.
Ojeda P, Ojeda I, Rubio G, Pineda F. Home‐based oral immunotherapy protocol with pasteurized egg for children allergic to hen's egg. Isr Med Assoc J. 2012;14(1):34‐39.
Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol. 1992;90(2):256‐262.
Pajno GB, Caminiti L, Salzano G, et al. Comparison between two maintenance feeding regimens after successful cow's milk oral desensitization. Pediatr Allergy Immunol. 2013;24(4):376‐381.
Pajno GB, Caminiti L, Ruggeri P, et al. Oral immunotherapy for cow's milk allergy with a weekly up‐dosing regimen: a randomized single‐blind controlled study. Ann Allergy Asthma Immunol. 2010;105(5):376‐381.
Palosuo K, Karisola P, Savinko T, Fyhrquist N, Alenius H, Mäkelä MJ. A randomized, open‐label trial of Hen's egg Oral immunotherapy: efficacy and humoral immune responses in 50 children. J Allergy Clin Immunol Pract. 2021;9(5):1892‐1901.e1.
Patriarca G, Nucera E, Pollastrini E, et al. Oral specific desensitization in food‐allergic children. Dig Dis Sci. 2007;52(7):1662‐1672.
Pérez‐Rangel I, Rodríguez Del Río P, Escudero C, Sánchez‐García S, Sánchez‐Hernández JJ, Ibáñez MD. Efficacy and safety of high‐dose rush oral immunotherapy in persistent egg allergic children: a randomized clinical trial. Ann Allergy Asthma Immunol. 2017;118(3):356‐364.e3.
Pongracic JA, Gagnon R, Sussman G, et al. Safety of epicutaneous immunotherapy in peanut‐allergic children: REALISE randomized clinical trial results. J Allergy Clin Immunol Pract. 2021;10(7):1864‐1873.e10.
Reier‐Nilsen T, Carlsen KCL, Michelsen MM, et al. Parent and child perception of quality of life in a randomized controlled peanut oral immunotherapy trial. Pediatr Allergy Immunol. 2019;30(6):638‐645.
Reier‐Nilsen T, Michelsen MM, Lødrup Carlsen KC, et al. Feasibility of desensitizing children highly allergic to peanut by high‐dose oral immunotherapy. Allergy. 2019;74(2):337‐348.
Salmivesi S, Korppi M, Mäkelä MJ, Paassilta M. Milk oral immunotherapy is effective in school‐aged children. Acta Paediatr. 2013;102(2):172‐176.
Sampson HA, Shreffler WG, Yang WH, et al. Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial. JAMA. 2017;318(18):1798‐1809.
Sánchez‐García S, Rodríguez del Río P, Escudero C, García‐Fernández C, Ramirez A, Ibáñez MD. Efficacy of oral immunotherapy protocol for specific oral tolerance induction in children with cow's milk allergy. Isr Med Assoc J. 2012;14(1):43‐47.
Sato S, Utsunomiya T, Imai T, et al. Wheat oral immunotherapy for wheat‐induced anaphylaxis. J Allergy Clin Immunol. 2015;136(4):1131‐1133.e7.
Scurlock AM, Burks AW, Sicherer SH, et al. Epicutaneous immunotherapy for treatment of peanut allergy: follow‐up from the consortium for food allergy research. J Allergy Clin Immunol. 2021;147(3):992‐1003.e5.
Skripak JM, Nash SD, Rowley H, et al. A randomized, double‐blind, placebo‐controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol. 2008;122(6):1154‐1160.
Staden U, Blumchen K, Blankenstein N, et al. Rush oral immunotherapy in children with persistent cow's milk allergy. J Allergy Clin Immunol. 2008;122(2):418‐419.
Sugiura S, Kitamura K, Makino A, et al. Slow low‐dose oral immunotherapy: threshold and immunological change. Allergol Int. 2020;69(4):601‐609.
Takahashi M, Taniuchi S, Soejima K, Hatano Y, Yamanouchi S, Kaneko K. Two‐weeks‐sustained unresponsiveness by oral immunotherapy using microwave heated cow's milk for children with cow's milk allergy. Allergy Asthma Clin Immunol. 2016;12(1):44.
Takaoka Y, Maeta A, Takahashi K, et al. Effectiveness and safety of double‐blind, placebo‐controlled, low‐dose Oral immunotherapy with low allergen egg‐containing cookies for severe Hen's egg allergy: a single‐center analysis. Int Arch Allergy Immunol. 2019;180(4):244‐249.
Takaoka Y, Yajima Y, Ito YM, et al. Single‐center noninferiority randomized trial on the efficacy and safety of low‐ and high‐dose rush oral milk immunotherapy for severe milk allergy. Int Arch Allergy Immunol. 2020;181(9):699‐705.
Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127(3):654‐660.
Vickery BP, Berglund JP, Burk CM, et al. Early oral immunotherapy in peanut‐allergic preschool children is safe and highly effective. J Allergy Clin Immunol. 2017;139(1):173‐181.e8.
Vickery BP, Vereda A, Nilsson C, et al. Continuous and daily Oral immunotherapy for Peanut allergy: results from a 2‐year open‐label follow‐on study. J Allergy Clin Immunol Pract. 2021;9(5):1879‐1889.e14.
PALISADE Group of Clinical Investigators, Vickery BP, Vereda A, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379(21):1991‐2001.
Yanagida N, Sato S, Asaumi T, Nagakura K, Ogura K, Ebisawa M. Safety and efficacy of low‐dose oral immunotherapy for hen's egg allergy in children. Int Arch Allergy Immunol. 2016;171(3–4):265‐268.
Yanagida N, Sato S, Asaumi T, Okada Y, Ogura K, Ebisawa M. A single‐center, case–control study of low‐dose‐induction oral immunotherapy with cow's milk. Int Arch Allergy Immunol. 2015;168(2):131‐137.
Zapatero L, Alonso E, Fuentes V, Martínez MI. Oral desensitization in children with cow's milk allergy. J Investig Allergol Clin Immunol. 2008;18(5):389‐396.
Zhong Y, Chew JML, Tan MM, Soh JY. Efficacy and safety of oral immunotherapy for peanut allergy: a pilot study in Singaporean children. Asia Pac Allergy. 2019;9(1):e1.
Alghamdi R, Alshaier R, Alotaibi A, et al. Immunotherapy effectiveness in treating Peanut hypersensitivity: a systemic review. Cureus. 2022;14(2):e21832.
Brożek JL, Terracciano L, Hsu J, et al. Oral immunotherapy for IgE‐mediated cow's milk allergy: a systematic review and meta‐analysis. Clin Exp Allergy. 2012;42(3):363‐374.
Calvani M, Giorgio V, Miceli Sopo S. Specific oral tolerance induction for food. A systematic review. Eur Ann Allergy Clin Immunol. 2010;42(1):11‐19.
Cao S, Borro M, Alonzi S, Sindher S, Nadeau K, Chinthrajah RS. Improvement in health‐related quality of life in food‐allergic patients: a meta‐analysis. J Allergy Clin Immunol Pract. 2021;9(10):3705‐3714.
Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta‐analysis of efficacy and safety. Lancet. 2019;393(10187):2222‐2232.
de Silva D, Rodríguez del Río P, de Jong NW, et al. Allergen immunotherapy and/or biologicals for IgE‐mediated food allergy: a systematic review and meta‐analysis. Allergy. 2022;77:1852‐1862.
Fisher HR, du Toit G, Lack G. Specific oral tolerance induction in food allergic children: is oral desensitisation more effective than allergen avoidance?: a meta‐analysis of published RCTs. Arch Dis Child. 2011;96(3):259‐264.
Grzeskowiak LE, Tao B, Knight E, Cohen‐Woods S, Chataway T. Adverse events associated with peanut oral immunotherapy in children ‐ a systematic review and meta‐analysis. Sci Rep. 2020;10(1):659.
Kristiansen M, Dhami S, Netuveli G, et al. Allergen immunotherapy for the prevention of allergy: a systematic review and meta‐analysis. Pediatr Allergy Immunol. 2017;28(1):18‐29.
Larenas‐Linnemann D, Blaiss M, Van Bever HP, Compalati E, Baena‐Cagnani CE. Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009–2012. Ann Allergy Asthma Immunol. 2013;110(6):402‐415.e9.
Martorell Calatayud C, Muriel García A, Martorell Aragonés A, de la Hoz Caballer B. Safety and efficacy profile and immunological changes associated with oral immunotherapy for IgE‐mediated cow's milk allergy in children: systematic review and meta‐analysis. J Investig Allergol Clin Immunol. 2014;24(5):298‐307.
Nurmatov U, Devereux G, Worth A, Healy L, Sheikh A. Effectiveness and safety of orally administered immunotherapy for food allergies: a systematic review and meta‐analysis. Br J Nutr. 2014;111(1):12‐22.
Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for IgE‐mediated food allergy: a systematic review and meta‐analysis. Allergy. 2017;72(8):1133‐1147.
Nurmatov U, Venderbosch I, Devereux G, Simons FE, Sheikh A. Allergen‐specific oral immunotherapy for peanut allergy. Cochrane Database Syst Rev. 2012;(9):Cd009014.
Romantsik O, Tosca MA, Zappettini S, Calevo MG. Oral and sublingual immunotherapy for egg allergy. Cochrane Database Syst Rev. 2018;4(4):CD010638.
Romantsik O, Tosca MA, Zappettini S, Calevo MG. Oral and sublingual immunotherapy for egg allergy. Cochrane Database Syst Rev. 2018;4(4):Cd010638.
Sheikh A, Nurmatov U, Venderbosch I, Bischoff E. Oral immunotherapy for the treatment of peanut allergy: systematic review of six case series studies. Prim Care Respir J. 2011;21(1):41‐49.
Sun J, Hui X, Ying W, Liu D, Wang X. Efficacy of allergen‐specific immunotherapy for peanut allergy: a meta‐analysis of randomized controlled trials. Allergy Asthma Proc. 2014;35(2):171‐177.
Xiong L, Lin J, Luo Y, Chen W, Dai J. The efficacy and safety of epicutaneous immunotherapy for allergic diseases: a systematic review and meta‐analysis. Int Arch Allergy Immunol. 2020;181(3):170‐182.
Yepes‐Nuñez JJ, Zhang Y, Roqué i Figuls M, et al. Immunotherapy (oral and sublingual) for food allergy to fruits. Cochrane Database Syst Rev. 2015;2015(11):Cd010522.
Yeung JP, Kloda LA, McDevitt J, Ben‐Shoshan M, Alizadehfar R. Oral immunotherapy for milk allergy. Cochrane Database Syst Rev. 2012;14(11):Cd009542.
NCT01781637. Peanut Reactivity Reduced by Oral Tolerance in an Anti‐IgE Clinical Trial. https://clinicaltrials.gov/show/NCT01781637 2013.
de Silva D, Singh C, Arasi S, et al. Systematic review of monotherapy with biologicals for children and adults with IgE‐mediated food allergy. Clin Transl Allergy. 2022;12(9):e12123.
Zuberbier T, Wood RA, Bindslev‐Jensen C, et al. Omalizumab in IgE‐mediated food allergy: a systematic review and meta‐analysis. J Allergy Clin Immunol Pract. 2022;11(4):1134‐1146.
Haddaway NRAUPCC, McGuinness LA. PRISMA2020: R package and ShinyApp for producing PRISMA 2020 compliant flow diagrams (Version 0.0.2), Zenodo. 2021.